Cargando…
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
Interstitial lung disease (ILD) is a serious side-effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment. Therefore, it is necessary to study underlying mechanisms for the development of pulmonary fibrosis induced by EGFR-TKI and potential approaches to attenuate...
Autores principales: | Li, Li, Huang, Wenting, Li, Kunlin, Zhang, Kejun, Lin, Caiyu, Han, Rui, Lu, Conghua, Wang, Yubo, Chen, Hengyi, Sun, Fenfen, He, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791254/ https://www.ncbi.nlm.nih.gov/pubmed/26497205 |
Ejemplares similares
-
Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1
por: Chen, Hengyi, et al.
Publicado: (2020) -
Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017) -
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016) -
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Lin, Caiyu, et al.
Publicado: (2021) -
Metformin Attenuates TGF-β1-Induced Fibrosis in Salivary Gland: A Preliminary Study
por: Wang, Lianhao, et al.
Publicado: (2023)